Epclusa 400 mg/100 mg FC tablet
PDF Leaflet Revision Date: 10 March 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of chronic hepatitis C infection in patients aged 12 years and older.
Dosage (summary)
One tablet (400 mg sofosbuvir/100 mg velpatasvir) once daily.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Amiodarone
- Rifampicin
- St. John's wort
Contraindications
- Hypersensitivity
- Pregnancy
- Concomitant use with strong P-gp/CYP inducers
Common side effects
- Headache
- Fatigue
- Nausea
Counselling Points
- Take with or without food
- Monitor for signs of bradycardia
- Do not double dose if missed
Serious warnings
- Severe bradycardia with amiodarone
- Hepatitis B reactivation risk
Important Disclaimer
The Epclusa 400 mg/100 mg FC tablet professional information leaflet below is the property of Gilead Sciences South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
